Trend in place and not much time to collect sub $1.00. The funds will be coming before Amgen deal is finalized by end of Jan. 15M up front as a deposit and non dilutive, impressive. Added at 0.85, I no longer think I'll get the pullback I wanted to add. GLTA
Funding and marketing partnership is a huge need here and it looks like Amgen will provide those.
ReadyToGo, a portfolio of wearable injectors for pre-filled, disposable devices that can be worn by a patient over periods; Imperium platform, a prefilled, disposable, and multi-day wearable insulin pump
* Amgen’s Neulasta Onpro kit proved to be a commercial success. It managed to acquire 19% of the total Neulasta patient share in fiscal 3Q15.
Guess we have an idea of Amgen's foresight in the 15M upfront to Unilife with it's better mousetrap. Wondering if Amgen has connections in the insulin world? A hint in that area and we are looking at a $1 billion dollar market cap in the near future.
Also will be seeing more insulins coming off market along with the inexpensive insulins now on the market becoming more effective using the insulin pump versus the newer expensive insulins. A money saving opportunity would get quick adoption.
Buyout and gouge consumer on drugs you bought by raising prices 300 to 500 percent. Wall Street bangs the drums and buys into this scam with your dollars. The big boyz in the club have already pocketed millions upon millions in their personal accounts and rode off into the sunset. Meanwhile the little guy will suffer as the game unravels.
The Onpro kit used is from Insulet which has close ties with Lilly and is a 2 billion plus company. That gives you an idea of the potential on the insulin pump Unilife introduced last summer. Are we looking at a better mousetrap? Amgen may be telling later this month.
Amgen is already an innovator in the specialty injector technology:
The Neulasta® Onpro™ kit includes a single dose of Neulasta® and a single-use On-body Injector. The On-body Injector is a small, lightweight delivery system designed to automatically administer Neulasta® the day after your chemo appointment. That means you may not have to return to the doctor just for a Neulasta® shot.
*It's good to have someone like that forward you $15M upfront and non dilutive with more to come with what I think is likely to be announced at the end of the month. Wall Street will be very happy to see Unilife turn the corner and start inking some big deals. Judging by the Onpro kit Amgen knows the value of what Unilife can offer.
Biologic makers looking to delivery devices to gain competitive edge
And from 2014
SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices
Current estimates value the global market for injectable drugs at $240 billion, giving injectables a 28% share of the overall drug market worldwide. This annual Drug Development & Delivery report on hand-held devices reveals that the injectables sector is witnessing some very specific trends that are affecting the market’s growth. For example, biologics are being attributed as the main driver for this growth because these are larger molecules that need to be administered by injection given their size and profile. The biologic drug market is expected to grow to $251 billion by 2018 and $900 billion by 2024.1 For these larger and more viscous biologic products, wearable injectors could prove invaluable. Single-use wearable or bolus injectors deliver precise amounts of drug in doses as high as 30mL. With approximately 250 molecules identified by Roots Analysis requiring wearable injectors, the bolus market is projected to generate $8 billion in device sales by 2024.
* Unilife really needs a well funded marketing partner and Big Pharma Amgen looks ideal.
10 consecutive days after closing above $1 you have Amgen buying their 19.9%, 16M plus shorts screaming to get out before Amgen cooperation begins and funds being able to buy in now that the stock is again listed.
Your updates are much appreciated.
What we do know:
* Debtors are required to work in good faith to reach a remedy that satisfies the creditor. So we know the two sides are likely working towards a settlement and that a lot of accounting and legal matters are being put to rest.
* Some bankruptcies are dismissed for the debtor's failure to comply with the requirements of the Code. When that happens, creditors are free to pursue collection according to state law. Sometimes cases originally classified as "no asset" cases blossom into asset cases
....If at any time before May 31, 2016, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed
Investors replacing day traders and the 19.9% Amgen is buying along with the 16M shares short need to hedge/cover or whatever will be gone and no longer holding down the price. Looks like a very good January shaping up. Then we get to see what Amgen can do with it's Big Pharma marketing and sales force in 2016.
Maybe better, Amgen knows how to scale up and has a vast sells network. Amgen obviously likes what they see in the technology and it's potential. Amgen getting it's foot in the door and having options to be the primary partner looks profitable for both. Other potential partners seeing Amgen's interest and investment will only heighten others interest and urgency. 2016 looking impressive and it's only just begun.
Amgen's interest just validating the potential Wall Street will see in Unilife.
Amgen has OK to buy 19.9% of shares along with the $15M (deposit). So with deposit I have to wonder what is coming later in the month. Why would any short be hanging around at this point?
The 19.9% and we have yet to see a filing where the 5% threshold has been crossed where a filing would be required.
Wild guess, if the two cooperate they have at least $100M in tax loss carry forwards that are not wasted. It's well above my understanding, tax law, but I'm sure Perelman's people know how to take full advantage of it.
With Amgen on board the marketing and funding will be taken to a whole new level. Generic and lower priced insulins getting more attention (equivalent efficiencies) will also benefit auto injector....in the near future as deals will be worked out with low cost insulin producers and insurance companies. If you know a diabetic ask them about the prohibitive cost buried in the insulin world. This one has a lot of potential and seeing todays Amgen news has me looking well into the future with this one. GLTA and congrats to those booking a quick 50 to 100 percent profit today. I think there is a lot more to come.
Siga will make it rewarding for Pharmathene to show patience and to be flexible in reaching a resolution. Siga is now insolvent and Pharmathene it's Creditor. The fact that Siga can come out of this with a couple of hundred million with full use of tax credits...
Tee, I'm thinking merger wondering what you see? The Siga shareholders were warned about a new stock being issued when their present stock has no current value.
Good thru Jan 31 then Unilife can freely negotiate with any and all interested partners. A very fluid contract of exclusive and nonexclusive rights that may be obtained (for more cash?). Seriously, Amgen has been looking at the various technologies for months and knows what Unilife potential can be if left to make deals with multiple partners. Looks like Amgen wants some ownership and will help with funds and business knowledge to advance the technologies???
Wild guessing but the "deposit" and open ended writing in the release makes me think Unilife is going to be a subsidiary of Amgen in the near future???
The 15M is only a deposit? Gives Amgen some exclusivity to look at technology until Jan 31 and decide on (not sure) buyout? Amgen knowing the broad injections technologies are more valuable if left to license out to other Big Pharmas. $15 million for a deposit is impressive. What is going on is for exclusive and non-exclusive rights, that is a very fluid contract. For Unisys I've always been impressed with the technology and felt somebody just didn't know how to put together a business plan and/or needed cash to create the market and alliances.
On board at 0.75, GLTA. What a horrible day for good news.
* this deal works or we are headed to zero
* this deal works and many years down the road we see a cash flow to start addressing the $80M debt?
* Amgen buyout with debt addressed and is anything left for shareholders?
Unilife pumping the deal and leaving out a lot of detail for shareholders willing to make a long term commitment. Guees the Art of the Deal has it's demands. GLTA